ANTIBODY AGAINST THE CSF-1R

摘要

The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.

主权项

1. An isolated nucleic acid encoding an antibody that specifically binds to human CSF-1R, wherein
(i) the antibody comprises:
(a) a heavy-chain variable region being defined by the following formula
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4wherein:FR1, FR2, FR3, and FR4 are each framework regions;CDR1, CDR2, and CDR3 are each complementarity determining regions;wherein:CDR1 has at least five consecutive amino acids of the sequence starting in position 45 and finishing in position 54 of SEQ ID NO:2, wherein said at least five consecutive amino acids include SEQ ID NO:11;CDR2 has at least five consecutive amino acids of the sequence starting in position 66 and finishing in position 87 of SEQ ID NO:2, wherein said at least five consecutive amino acids include SEQ ID NO:12; andCDR3 has at least five consecutive amino acids of the sequence starting in position 117 and finishing in position 126 of SEQ ID NO:2, wherein said at least five consecutive amino acids include SEQ ID NO:13;and(b) a light-chain variable region being defined by the following formula
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4wherein:FR1, FR2, FR3, and FR4 are each framework regions;CDR1, CDR2, and CDR3 are each complementarity determining regions;wherein:CDR1 has at least five consecutive amino acids of the sequence starting in position 44 and finishing in position 56 of SEQ ID NO:4, wherein said at least five consecutive amino acids include SEQ ID NO:14;CDR2 has at least five consecutive amino acids of the sequence starting in position 66 and finishing in position 76 of SEQ ID NO:4, wherein said at least five consecutive amino acids include SEQ ID NO:15; andCDR3 has at least five consecutive amino acids of the sequence starting in position 109 and finishing in position 117 of SEQ ID NO:4, wherein said at least five consecutive amino acids include SEQ ID NO:16.and
(ii) the antibody has at least one of the following advantageous properties: it binds to one epitope located between position amino acids 20 to 41 of SEQ ID NO:29; it does not bind to an epitope located between position amino acids 42 to 90 of SEQ ID NO:29, and/or between position amino acids 91 to 104 of SEQ ID NO:29; it does not bind to an epitope located between position amino acids 105 to 199 of SEQ ID NO:29; and it does not bind to an epitope located between position amino acids 200 to 298 of SEQ ID NO:29.